The ClinicianThe ClinicianКлиницист1818-83382412-8775Publishing House ABV Press3110.17650/1818-8338-2013-2-64-72LECTIONЛЕКЦИЯASTHENIA IN PATIENTS WITH CHRONIC NEUROLOGICAL DISEASESАстения у пациентов с хроническими неврологическими заболеваниямиShchukinI. A.ЩукинИ. А.
Russian Federation
ivashchukin@gmail.comLebedevaA. V.ЛебедеваА. В.
Russian Federation
ChubykinV. I.ЧубыкинВ. И.
Russian Federation
SorokoletovS. M.СороколетовС. М.
Russian Federation
SoldatovM. A.СолдатовМ. А.
Russian Federation
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia N.I. Pirogov City Clinical Hospital Оne, Moscow Healthcare DepartmenГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздрава России ГБУЗ «Городская клиническая больница № 1 им. Н.И. Пирогова» Департамента здравоохранения г. МосквыN.I. Pirogov City Clinical Hospital Оne, Moscow Healthcare DepartmenГБУЗ «Городская клиническая больница № 1 им. Н.И. Пирогова» Департамента здравоохранения г. Москвы150420137264721407201414072014Copyright ©; 2013, Shchukin I.A., Lebedeva A.V., Chubykin V.I., Sorokoletov S.M., Soldatov M.A.Copyright ©; 2013, Щукин И.А., Лебедева А.В., Чубыкин В.И., Сороколетов С.М., Солдатов М.А.2013Shchukin I.A., Lebedeva A.V., Chubykin V.I., Sorokoletov S.M., Soldatov M.A.Щукин И.А., Лебедева А.В., Чубыкин В.И., Сороколетов С.М., Солдатов М.А.https://creativecommons.org/licenses/by/4.0https://klinitsist.abvpress.ru/Klin/article/view/31

The paper considers the basic mechanisms for the occurrence of asthenic syndrome in chronic neurological diseases. It shows the significance ofthis problem in nosological entities, such as stroke sequels, multiple sclerosis, and Parkinson’s disease. The main asthenia diagnostic scales aredescribed. Possible therapeutic strategies aimed at reducing the degree of asthenia in neurological patients are also presented.

В статье рассмотрены основные механизмы возникновения астенического синдрома при хронических неврологических заболеваниях. Показана значимость данной проблемы при таких нозологиях, как последствия острых нарушений мозгового кровообращения, рассеянный склероз и болезнь Паркинсона. Описаны основные диагностические шкалы для оценки астении. Также представлены возможные терапевтические стратегии, направленные на уменьшение выраженности астении у неврологических пациентов.

astheniastrokemultiple sclerosisParkinson’s diseaseidebenoneастенияинсультрассеянный склерозболезнь Паркинсонаидебенон1. Zwarts M.J., Bleijenberg G., van Engelen B.G. Clinical neurophysiology of fatigue. Clin NeurophysiolZwarts M.J., Bleijenberg G., van Engelen B.G. Clinical neurophysiology of fatigue. Clin Neurophysiol2008;119(1):2–10.;119(1):2–10.2. Adams R.D., Victor M., Ropper A.H. Fatigue, asthenia, anxiety and depressive reactions. In: Adams R.D., Victor M., Ropper A.H. (eds.) Principles of neurology. 6th edn. New York: McGraw-Hill, 1997.Adams R.D., Victor M., Ropper A.H. Fatigue, asthenia, anxiety and depressive reactions. In: Adams R.D., Victor M., Ropper A.H. (eds.) Principles of neurology. 6th edn. New York: McGraw-Hill, 1997.Pp. 497–507.3. Branas P., Jordan R., Fry-Smith A. et al. Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technol Assess 2000;4(27):1–61.Branas P., Jordan R., Fry-Smith A. et al. Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technol Assess 2000;4(27):1–61.4. Abbot N.C., Spence V. Chronic fatigue syndrome. Lancet 2006;367(9522):1574;author reply 1575.Abbot N.C., Spence V. Chronic fatigue syndrome. Lancet 2006;367(9522):1574;author reply 1575.5. Hemmett L., Holmes J., Barnes M., Russell N. What drives quality of life in multiple sclerosis? QJM 2004;97(10):671–6.Hemmett L., Holmes J., Barnes M., Russell N. What drives quality of life in multiple sclerosis? QJM 2004;97(10):671–6.6. Jaracz K., Mielcarek L., Kozubski W. Clinical and psychological correlates of poststroke fatigue. Preliminary results. Neurol Neurochir Pol 2007;41(1):36–43.Jaracz K., Mielcarek L., Kozubski W. Clinical and psychological correlates of poststroke fatigue. Preliminary results. Neurol Neurochir Pol 2007;41(1):36–43.7. Oken B.S., Kishiyama S., Zajdel D. et al. Randomized controlled trial of yoga and exercise in multiple sclerosis. Neurology 2004;62(11):2058–64.Oken B.S., Kishiyama S., Zajdel D. et al. Randomized controlled trial of yoga and exercise in multiple sclerosis. Neurology 2004;62(11):2058–64.8. Barbour V.L., Mead G.E. Fatigue after Stroke: The Patient’s Perspective. Stroke Res Treat 2012;2012:863031.Barbour V.L., Mead G.E. Fatigue after Stroke: The Patient’s Perspective. Stroke Res Treat 2012;2012:863031.9. Mead G.E., Graham C., Dorman P. et al. Fatigue after stroke: baseline predictors and influence on survival. analysis of data from UK patients recruited in the International Stroke Trial. PLoS One 2011;6(3):e16988.Mead G.E., Graham C., Dorman P. et al. Fatigue after stroke: baseline predictors and influence on survival. analysis of data from UK patients recruited in the International Stroke Trial. PLoS One 2011;6(3):e16988.10. McKechnie F., Lewis S., Mead G. A pilot observational study of the association between fatigue after stroke and Creactive protein. J R Coll Physicians Edinb 2010;40(1):9–12.McKechnie F., Lewis S., Mead G. A pilot observational study of the association between fatigue after stroke and Creactive protein. J R Coll Physicians Edinb 2010;40(1):9–12.11. Ingles J.L., Eskes G.A., Phillips S.J. Fatigue after stroke. Arch Phys Med Rehabil 1999;80(2):173–8.Ingles J.L., Eskes G.A., Phillips S.J. Fatigue after stroke. Arch Phys Med Rehabil 1999;80(2):173–8.12. Winward C., Sackley C., Metha Z., Rothwell P.M. A population-based study of the prevalence of fatigue after transient ischemic attack and minor stroke. Stroke 2009;40(3):757–61.Winward C., Sackley C., Metha Z., Rothwell P.M. A population-based study of the prevalence of fatigue after transient ischemic attack and minor stroke. Stroke 2009;40(3):757–61.13. Glader E.L., Stegmayr B., Asplund K. Poststroke fatigue: a 2-year follow-up study of stroke patients in Sweden. Stroke 2002;33(5):1327–33.Glader E.L., Stegmayr B., Asplund K. Poststroke fatigue: a 2-year follow-up study of stroke patients in Sweden. Stroke 2002;33(5):1327–33.14. de Coster L., Leentjens A.F., Lodder J., Verhey F.R. The sensitivity of somatic symptoms in post-stroke depression: a discriminant analytic approach. Int J Geriatr Psychiatry 2005;20(4):358–62.de Coster L., Leentjens A.F., Lodder J., Verhey F.R. The sensitivity of somatic symptoms in post-stroke depression: a discriminant analytic approach. Int J Geriatr Psychiatry 2005;20(4):358–62.15. Lewis S.J., Barugh A.J., Greig C.A. et al. Is fatigue after stroke associated with physical deconditioning? A cross-sectional study in ambulatory stroke survivors. Arch Phys Med Rehabil 2011;92(2):295–8.Lewis S.J., Barugh A.J., Greig C.A. et al. Is fatigue after stroke associated with physical deconditioning? A cross-sectional study in ambulatory stroke survivors. Arch Phys Med Rehabil 2011;92(2):295–8.16. Christensen D., Johnsen S.P., Watt T. et al. Dimensions of post-stroke fatigue: a two-year follow-up study. Cerebrovasc Dis 2008;26(2):134–41.Christensen D., Johnsen S.P., Watt T. et al. Dimensions of post-stroke fatigue: a two-year follow-up study. Cerebrovasc Dis 2008;26(2):134–41.17. Carlsson G.E., Forsberg-Warleby G., Moller A., Blomstrand C. Comparison of life satisfaction within couples one year after a partner’s stroke. J Rehabil Med 2007;39(3):219–24.Carlsson G.E., Forsberg-Warleby G., Moller A., Blomstrand C. Comparison of life satisfaction within couples one year after a partner’s stroke. J Rehabil Med 2007;39(3):219–24.18. Schon E.A., Manfredi G. Neuronal degeneration and mitochondrial dysfunction. J Clin Invest 2003;111(3): 303–12.Schon E.A., Manfredi G. Neuronal degeneration and mitochondrial dysfunction. J Clin Invest 2003;111(3): 303–12.19. Bendz M. The first year of rehabilitation after a stroke – from two perspectives. Scand J Caring Sci 2003;17(3):215–22.Bendz M. The first year of rehabilitation after a stroke – from two perspectives. Scand J Caring Sci 2003;17(3):215–22.20. Rasova K., Havrdova E., Brandejsky P. et al. Comparison of the influence of different rehabilitation programmes on clinical, spirometric and spiroergometric parameters in patients with multipleRasova K., Havrdova E., Brandejsky P. et al. Comparison of the influence of different rehabilitation programmes on clinical, spirometric and spiroergometric parameters in patients with multiplesclerosis. Mult Scler 2006;12(2):227–34.21. Naess H., Nyland H.I., Thomassen L. et al. Fatigue at long-term follow-up in young adults with cerebral infarction. Cerebrovasc Dis 2005;20(4):245–50.Naess H., Nyland H.I., Thomassen L. et al. Fatigue at long-term follow-up in young adults with cerebral infarction. Cerebrovasc Dis 2005;20(4):245–50.22. Mathiowetz V. Test-retest reliability and convergent validity of the Fatigue Impact Scale for persons with multiple sclerosis. Am J Occup Ther 2003;57(4):389–95.Mathiowetz V. Test-retest reliability and convergent validity of the Fatigue Impact Scale for persons with multiple sclerosis. Am J Occup Ther 2003;57(4):389–95.23. Lerdal A., Wahl A., Rustoen T. et al. Fatigue in the general population: a translation and test of the psychometric properties of the Norwegian version of the Fatigue Severity Scale. Scand J PublicLerdal A., Wahl A., Rustoen T. et al. Fatigue in the general population: a translation and test of the psychometric properties of the Norwegian version of the Fatigue Severity Scale. Scand J PublicHealth 2005;33(2):123–30.24. Appelros P. Prevalence and predictors of pain and fatigue after stroke: a population-based study. Int J Rehabil Res 2006;29(4):329–33.Appelros P. Prevalence and predictors of pain and fatigue after stroke: a population-based study. Int J Rehabil Res 2006;29(4):329–33.25. Skaner Y., Nilsson G.H., Sundquist K. et al. Self-rated health, symptoms of depression and general symptoms at 3 and 12 months after a first-ever stroke: a municipality-based study in Sweden. BMCSkaner Y., Nilsson G.H., Sundquist K. et al. Self-rated health, symptoms of depression and general symptoms at 3 and 12 months after a first-ever stroke: a municipality-based study in Sweden. BMCFam Pract 2007;8:61.26. Lapierre Y., Hum S. Treating fatigue. Int MS J 2007;14(2):64–71.Lapierre Y., Hum S. Treating fatigue. Int MS J 2007;14(2):64–71.27. Purebl G., Birkas E., Csoboth C. et al. The relationship of biological and psychological risk factors of cardiovascular disorders in a large-scale national representative community survey. Behav Med 2006;31(4):133–9.Purebl G., Birkas E., Csoboth C. et al. The relationship of biological and psychological risk factors of cardiovascular disorders in a large-scale national representative community survey. Behav Med 2006;31(4):133–9.28. Rampello A., Franceschini M., Piepoli M. et al. Effect of aerobic training on walking capacity and maximal exercise tolerance in patients with multiple sclerosis: a randomized crossover controlledRampello A., Franceschini M., Piepoli M. et al. Effect of aerobic training on walking capacity and maximal exercise tolerance in patients with multiple sclerosis: a randomized crossover controlledstudy. Phys Ther 2007;87(5):545–55.29. Giovannoni G. Multiple sclerosis related fatigue. J Neurol Neurosurg Psychiatry 2006;77(1):2–3.Giovannoni G. Multiple sclerosis related fatigue. J Neurol Neurosurg Psychiatry 2006;77(1):2–3.30. Gottschalk M., Kumpfel T., Flachenecker P. et al. Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis. Arch Neurol 2005;62(2):277–80.Gottschalk M., Kumpfel T., Flachenecker P. et al. Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis. Arch Neurol 2005;62(2):277–80.31. Roelcke U., Kappos L., Lechner-Scott J. et al. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology 1997;48(6):1566–71.Roelcke U., Kappos L., Lechner-Scott J. et al. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology 1997;48(6):1566–71.32. White A.T., Wilson T.E., Davis S.L. et al. Effect of precooling on physical performance in multiple sclerosis. Mult Scler 2000;6(3):176–80.White A.T., Wilson T.E., Davis S.L. et al. Effect of precooling on physical performance in multiple sclerosis. Mult Scler 2000;6(3):176–80.33. Romani A., Bergamaschi R., Candeloro E. et al. Fatigue in multiple sclerosis: multidimensional assessment and response to symptomatic treatment. Mult Scler 2004;10(4):462–8.Romani A., Bergamaschi R., Candeloro E. et al. Fatigue in multiple sclerosis: multidimensional assessment and response to symptomatic treatment. Mult Scler 2004;10(4):462–8.34. Attarian H.P., Brown K.M., Duntley S.P. et al. The relationship of sleep disturbancesand fatigue in multiple sclerosis. Arch Neurol 2004;61(4):525–8.Attarian H.P., Brown K.M., Duntley S.P. et al. The relationship of sleep disturbancesand fatigue in multiple sclerosis. Arch Neurol 2004;61(4):525–8.35. Nausieda P.A., Weiner W.J., Kaplan L.R. et al. Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol 1982;5(2):183–94.Nausieda P.A., Weiner W.J., Kaplan L.R. et al. Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol 1982;5(2):183–94.36. Hagell P., Brundin L. Towards an understanding of fatigue in Parkinson disease. J Neurol Neurosurg Psychiatry 2009;80(5):489–92.Hagell P., Brundin L. Towards an understanding of fatigue in Parkinson disease. J Neurol Neurosurg Psychiatry 2009;80(5):489–92.37. Barone P., Antonini A., Colosimo C. et al.; PRIAMO study group. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 2009;24(11):1641–9.Barone P., Antonini A., Colosimo C. et al.; PRIAMO study group. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 2009;24(11):1641–9.38. Abe K., Takanashi M., Yanagihara T. Fatigue in patients with Parkinson’s disease. Behav Neurol 2000;12(3):103–6.Abe K., Takanashi M., Yanagihara T. Fatigue in patients with Parkinson’s disease. Behav Neurol 2000;12(3):103–6.39. Schifitto G., Friedman J.H., Oakes D. et al.; Parkinson Study Group ELLDOPA Investigators. Fatigue in levodopa-naive subjects with Parkinson disease. Neurology 2008;71(7):481–5.Schifitto G., Friedman J.H., Oakes D. et al.; Parkinson Study Group ELLDOPA Investigators. Fatigue in levodopa-naive subjects with Parkinson disease. Neurology 2008;71(7):481–5.40. Ghika J., Ghika-Schmid F., Frankhauser H. et al. Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson’s disease: neuropsychological and neurological sideGhika J., Ghika-Schmid F., Frankhauser H. et al. Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson’s disease: neuropsychological and neurological sideeffects. Report of four cases and review of literature. J Neurosurg 1999;91(2):313–21.41. Pavese N., Metta V., Bose S.K. et al. Fatigue in Parkinson’s disease is linked to striatal and limbic serotonergic dysfunction. Brain 2010;133(11):3434–43.Pavese N., Metta V., Bose S.K. et al. Fatigue in Parkinson’s disease is linked to striatal and limbic serotonergic dysfunction. Brain 2010;133(11):3434–43.42. Karlsen K., Larsen J.P., Tandberg E., Jørgensen K. Fatigue in patients with Parkinson’s disease. Mov Disord 1999;14(2):237–41.Karlsen K., Larsen J.P., Tandberg E., Jørgensen K. Fatigue in patients with Parkinson’s disease. Mov Disord 1999;14(2):237–41.43. Stacy M. Sleep disorders in Parkinson’s disease: epidemiology and management. Drugs Aging 2002;19(10):733–9.Stacy M. Sleep disorders in Parkinson’s disease: epidemiology and management. Drugs Aging 2002;19(10):733–9.44. Goulart F.O., Godke B.A., Borges V. et al. Fatigue in a cohort of geriatric patients with and without Parkinson’s disease. Braz J Med Biol Res. 2009;42(8):771–5.Goulart F.O., Godke B.A., Borges V. et al. Fatigue in a cohort of geriatric patients with and without Parkinson’s disease. Braz J Med Biol Res. 2009;42(8):771–5.45. Metta V., Logishetty K., Martinez-Martin P. et al. The possible clinical predictors of fatigue in Parkinson's disease: a study of 135 patients as part of international nonmotor scale validationMetta V., Logishetty K., Martinez-Martin P. et al. The possible clinical predictors of fatigue in Parkinson's disease: a study of 135 patients as part of international nonmotor scale validationproject. Parkinsons Dis 2011;2011:125271.46. Mead G., Lynch J., Greig C. et al. Evaluation of fatigue scales in stroke patients. Stroke 2007;38(7):2090–5.Mead G., Lynch J., Greig C. et al. Evaluation of fatigue scales in stroke patients. Stroke 2007;38(7):2090–5.47. Kos D., Nagels G., D’Hooghe M.B. et al. A rapid screening tool for fatigue impact in multiple sclerosis. BMC Neurol 2006;6:27.Kos D., Nagels G., D’Hooghe M.B. et al. A rapid screening tool for fatigue impact in multiple sclerosis. BMC Neurol 2006;6:27.48. Lou J.S., Kearns G., Oken B. et al. Exacerbated physical fatigue and mental fatigue in Parkinson’s disease. Mov Disord 2001;16(2):190–6.Lou J.S., Kearns G., Oken B. et al. Exacerbated physical fatigue and mental fatigue in Parkinson’s disease. Mov Disord 2001;16(2):190–6.49. Mathiowetz V., Matuska K.M., Murphy M.E. Efficacy of an energy conservation course for persons with multiple sclerosis. Arch Phys Med Rehabil 2001;82(4):449–56.Mathiowetz V., Matuska K.M., Murphy M.E. Efficacy of an energy conservation course for persons with multiple sclerosis. Arch Phys Med Rehabil 2001;82(4):449–56.50. Armstrong J.S., Whiteman M., Rose P., Jones D.P. The Coenzyme Q10 analog decylubiquinone inhibits the redox-activated mitochondrial permeability transition. Role of mitochondrial respiratory complex III. J Biol Chem 2003;278(49):49079–84.Armstrong J.S., Whiteman M., Rose P., Jones D.P. The Coenzyme Q10 analog decylubiquinone inhibits the redox-activated mitochondrial permeability transition. Role of mitochondrial respiratory complex III. J Biol Chem 2003;278(49):49079–84.51. Mordente A., Martorana G.E., Minotti G., Giardina B. Antioxidant properties of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (idebenone). Chem Res Toxicol 1998;11(1):54–63.Mordente A., Martorana G.E., Minotti G., Giardina B. Antioxidant properties of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (idebenone). Chem Res Toxicol 1998;11(1):54–63.52. Weyer G., Babej-Dolle R.M., Hadler D. et al. A controlled study of two doses of idebenone in the treatment of Alzheimer's disease. Neuropsychobiol 1997;36(2):73–82.Weyer G., Babej-Dolle R.M., Hadler D. et al. A controlled study of two doses of idebenone in the treatment of Alzheimer's disease. Neuropsychobiol 1997;36(2):73–82.53. Arnold P., Kuntzer T., Boulat O. et al. Idebenone may improve patients with Friedreich's ataxia in increasing lipid peroxidation (Abstract). J Neurol 2002;249(1 Suppl):I162.Arnold P., Kuntzer T., Boulat O. et al. Idebenone may improve patients with Friedreich's ataxia in increasing lipid peroxidation (Abstract). J Neurol 2002;249(1 Suppl):I162.54. Воронкова К.В., Мелешков М.Н. Применение нобена (идебенона) в терапии деменции и нарушений памяти, не достигших степени деменции. Журн неврол и психиатр 2008;108(4):27–32.Воронкова К.В., Мелешков М.Н. Применение нобена (идебенона) в терапии деменции и нарушений памяти, не достигших степени деменции. Журн неврол и психиатр 2008;108(4):27–32.